Comparator: Rosiglitazone — Competitive Intelligence Brief

Comparator: Rosiglitazone (Comparator: Rosiglitazone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thiazolidinedione. Area: Diabetes.

phase 3 Thiazolidinedione PPAR-γ (Peroxisome proliferator-activated receptor gamma) Diabetes Small molecule

Target snapshot

Comparator: Rosiglitazone (Comparator: Rosiglitazone) — Merck Sharp & Dohme LLC. Rosiglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose levels.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Comparator: Rosiglitazone TARGET	Comparator: Rosiglitazone	Merck Sharp & Dohme LLC	phase 3	Thiazolidinedione	PPAR-γ (Peroxisome proliferator-activated receptor gamma)
oral hypoglycemic agents	oral hypoglycemic agents	Queen Elizabeth II Health Sciences Centre	marketed	Oral hypoglycemic agents (multiple classes: sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors)
pioglitazone + simvastatin	pioglitazone + simvastatin	University of Leipzig	marketed	Thiazolidinedione + HMG-CoA reductase inhibitor combination	PPAR-γ (pioglitazone); HMG-CoA reductase (simvastatin)
alogliptin + pioglitazone	alogliptin + pioglitazone	Kun-Ho Yoon	marketed	DPP-4 inhibitor + thiazolidinedione	DPP-4 and PPAR-γ
Actos (Pioglitazone)	Actos (Pioglitazone)	Taipei Veterans General Hospital, Taiwan	marketed	Thiazolidinediones	PPAR-γ
metformin\pioglitazone\exenatide	metformin\pioglitazone\exenatide	The University of Texas Health Science Center at San Antonio	marketed	Combination antidiabetic agent (biguanide + thiazolidinedione + GLP-1 receptor agonist)	Multiple: AMPK pathway (metformin), PPAR-γ (pioglitazone), GLP-1 receptor (exenatide)
Rosiglitazone and Pegasys/Ribavirin	Rosiglitazone and Pegasys/Ribavirin	Beth Israel Medical Center	marketed	Thiazolidinedione (rosiglitazone) combined with pegylated interferon alfa-2a and nucleoside analog (ribavirin)	PPAR-γ (rosiglitazone); Interferon-α receptor and HCV NS5B polymerase (pegasys/ribavirin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thiazolidinedione class)

1. Merck Sharp & Dohme LLC · 3 drugs in this class
2. GlaxoSmithKline · 1 drug in this class
3. Medical University of South Carolina · 1 drug in this class
4. National Cheng-Kung University Hospital · 1 drug in this class